These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24743239)

  • 1. Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.
    U M; Talevich E; Katiyar S; Rasheed K; Kannan N
    PLoS Comput Biol; 2014 Apr; 10(4):e1003545. PubMed ID: 24743239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence and structure signatures of cancer mutation hotspots in protein kinases.
    Dixit A; Yi L; Gowthaman R; Torkamani A; Schork NJ; Verkhivker GM
    PLoS One; 2009 Oct; 4(10):e7485. PubMed ID: 19834613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated mutations are preferentially distributed in protein kinase functional sites.
    Izarzugaza JM; Redfern OC; Orengo CA; Valencia A
    Proteins; 2009 Dec; 77(4):892-903. PubMed ID: 19626714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
    Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
    Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
    Dixit A; Verkhivker GM
    Comput Math Methods Med; 2014; 2014():653487. PubMed ID: 24817905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis of targeting protein kinases in cancer therapeutics.
    Tsai CJ; Nussinov R
    Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of cancer driver mutations in protein kinases.
    Torkamani A; Schork NJ
    Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
    Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
    Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX
    Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prioritization of pathogenic mutations in the protein kinase superfamily.
    Izarzugaza JM; del Pozo A; Vazquez M; Valencia A
    BMC Genomics; 2012 Jun; 13 Suppl 4(Suppl 4):S3. PubMed ID: 22759651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ProKinO: an ontology for integrative analysis of protein kinases in cancer.
    Gosal G; Kochut KJ; Kannan N
    PLoS One; 2011; 6(12):e28782. PubMed ID: 22194913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
    Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
    Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
    Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
    Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of Driver Kinases from Next-Generation Sequencing Data.
    Leonidou A; Peck B; Natrajan R
    Methods Mol Biol; 2017; 1636():179-195. PubMed ID: 28730480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain landscapes of somatic mutations in cancer.
    Nehrt NL; Peterson TA; Park D; Kann MG
    BMC Genomics; 2012 Jun; 13 Suppl 4(Suppl 4):S9. PubMed ID: 22759657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.